ANIX - CIK 0000715446
The table below shows Anixa Biosciences Inc's balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.55M | $1.50M | $1.91M | $1.05M | $1.23M | $995.00K |
| Short-term investments | $12.65M | $14.53M | $13.69M | $16.20M | $19.52M | $22.24M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $15.05M |
| $17.45M |
| $16.77M |
| $18.69M |
| $22.67M |
| $24.21M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $15.23M | $17.65M | $16.98M | $18.91M | $22.91M | $24.36M |
| Accounts payable | $148.00K | $276.00K | $284.00K | $600.00K | $302.00K | $215.00K |
| Total current liabilities | $1.24M | $2.07M | $1.89M | $2.00M | $2.00M | $1.68M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $1.39M | $2.24M | $2.07M | $2.19M | $2.22M | $1.77M |
| Retained earnings | -$254.24M | -$248.98M | -$246.72M | -$243.93M | -$237.87M | -$234.59M |
| Total equity | $15.08M | $16.59M | $16.07M | $17.85M | $21.77M | $23.62M |